What Is a Radiotracer?

A radiotracer is a radioactively labeled compound used to follow, or "trace," a specific biological process or chemical pathway within a living system. It consists of two components: a carrier molecule that targets a particular tissue, receptor, or metabolic pathway, and a radioactive atom bonded to that carrier. As the compound travels through the body, detectors positioned outside the patient capture the emitted radiation and reconstruct images of the tracer's distribution. Radiotracers are the functional core of nuclear medicine and have enabled noninvasive assessment of physiology in ways that conventional anatomical imaging cannot provide.

The field draws its scientific roots from radiochemistry, nuclear physics, and pharmacology. Early work in the mid-twentieth century established that small amounts of radioactive isotopes could be administered safely and tracked in vivo, and subsequent advances in detector technology and radiolabeling chemistry expanded the range of measurable processes dramatically. According to the National Academies' review of nuclear medicine innovation, approximately 20 million nuclear medicine procedures are performed annually in U.S. hospitals alone, with radiotracers at the center of nearly all of them.

Radionuclide Selection

The choice of radionuclide determines the imaging modality, the radiation dose, and the practical window in which imaging must occur. Technetium-99m, with a half-life of six hours and a gamma emission well-suited to gamma camera detection, dominates single-photon imaging and accounts for the majority of diagnostic procedures worldwide. For positron emission tomography (PET), fluorine-18 is the most widely used isotope, prized for its 110-minute half-life and the clean annihilation photons it produces. Carbon-11 and nitrogen-13 extend the toolkit to compounds that can incorporate biologically native atoms, though their shorter half-lives require an on-site cyclotron. Radionuclide availability, production cost, and radiation safety are all weighed in selecting the appropriate isotope for a given clinical or research application.

Synthesis and Labeling

Producing a radiotracer requires attaching the chosen radionuclide to the carrier molecule without altering the molecule's biological behavior. This synthesis must be completed rapidly, particularly when short-lived isotopes are involved, and the product must meet radiochemical purity standards before administration. Automated synthesis modules have become standard in PET radiopharmacies, allowing consistent production of compounds such as fluorodeoxyglucose (FDG), which mimics glucose uptake and is the most widely used PET radiotracer. Peptide and antibody labeling extends the approach to larger biomolecules that can target specific cell surface receptors, opening pathways for both diagnostic imaging and targeted radionuclide therapy.

PET and SPECT Imaging

The two principal imaging platforms that consume radiotracers are positron emission tomography and single-photon emission computed tomography (SPECT). PET detects the paired 511-keV photons produced when a positron annihilates with an electron, enabling quantitative measurement of tracer concentration with high sensitivity. SPECT uses rotating gamma cameras to acquire three-dimensional images from single-photon emitters, offering wider availability at lower cost. Combined PET/CT and PET/MRI systems align the functional radiotracer image with high-resolution anatomical data, a combination that the National Institutes of Health credits as central to modern cancer staging practice. The IAEA's nuclear medicine program coordinates global efforts to ensure equitable access to radiotracer production infrastructure, recognizing that supply chain stability is as important as scientific development.

Applications

Radiotracers have applications in a wide range of clinical and research domains, including:

• Oncology, for tumor detection, staging, and treatment response monitoring using FDG-PET
• Cardiology, for myocardial perfusion imaging and assessment of cardiac viability
• Neurology, for mapping dopaminergic pathways in Parkinson's disease and amyloid deposition in Alzheimer's disease
• Drug development, where carbon-11 or fluorine-18 labeled candidate compounds reveal pharmacokinetic behavior in early clinical trials
• Targeted radionuclide therapy, where alpha- or beta-emitting tracers deliver cytotoxic doses selectively to tumor tissue